Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price shot up 1.6% on Thursday . The company traded as high as C$1.98 and last traded at C$1.87. 29,147 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 102,571 shares. The stock had previously closed at C$1.84.
Medicenna Therapeutics Trading Down 7.5 %
The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The company has a market capitalization of C$132.22 million, a P/E ratio of -4.55 and a beta of 1.21. The company’s fifty day simple moving average is C$1.94 and its 200-day simple moving average is C$2.04.
About Medicenna Therapeutics
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- ETF Screener: Uses and Step-by-Step Guide
- Top 3 ETFs to Hedge Against Inflation in 2025
- Stock Sentiment Analysis: How it Works
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
